Shin Nippon Biomedical Laboratories Acquires Satsuma Pharmaceuticals

Shionogi Acquires Tetra Therapeutics

May 26, 2020

Biotechnology

Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.

Asahi Kasei Medical Acquires Bionova Scientific

April 14, 2022

Biotechnology

Asahi Kasei Medical agreed to wholly acquire Bionova Scientific, a Fremont, California-based biopharmaceutical CDMO that provides process development and GMP-compliant manufacturing services for next-generation antibody drugs. The acquisition, executed through a U.S. subsidiary, expands Asahi Kasei Medical's bioprocess and CDMO capabilities to better serve biologics developers and accelerate growth of its bioprocess business; closing is subject to regulatory clearances.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

SD Biosensor and SJL Partners Acquire Meridian Bioscience for $1.53B

July 7, 2022

Medical Devices

A consortium led by SD Biosensor and private equity firm SJL Partners agreed to acquire Meridian Bioscience in an all-cash transaction valued at approximately $1.53 billion ( $34.00 per share). The deal will take Meridian private and is intended to accelerate SD Biosensor's entry into the U.S. in-vitro diagnostics market while leveraging Meridian's U.S. distribution network and product portfolio.

Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation

February 7, 2025

Pharmaceuticals

Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) in a carve-out from Mitsubishi Chemical Group Corporation for approximately 510 billion JPY (about $3.3 billion). The deal, led by Bain’s Private Equity teams in Asia and North America together with its Life Sciences group, will create an independent, standalone Japanese pharma platform focused on drug discovery and development across immunology, CNS, vaccines, diabetes and other priority areas; the transaction is expected to close in Q3 2025.